EA201692310A1 - Состав церитиниба - Google Patents

Состав церитиниба

Info

Publication number
EA201692310A1
EA201692310A1 EA201692310A EA201692310A EA201692310A1 EA 201692310 A1 EA201692310 A1 EA 201692310A1 EA 201692310 A EA201692310 A EA 201692310A EA 201692310 A EA201692310 A EA 201692310A EA 201692310 A1 EA201692310 A1 EA 201692310A1
Authority
EA
Eurasian Patent Office
Prior art keywords
composition
binder
relates
ceritiniba
tablet
Prior art date
Application number
EA201692310A
Other languages
English (en)
Other versions
EA036922B1 (ru
Inventor
Себастьен Брелль
Зимон Энсслин
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53298568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201692310(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201692310A1 publication Critical patent/EA201692310A1/ru
Publication of EA036922B1 publication Critical patent/EA036922B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Настоящее изобретение относится к новой фармацевтической композиции, содержащей церитиниб. В частности, она относится к таблетке, которую получают влажным гранулированием, где в качестве связующего вещества используют повидон. Следующим признаком композиции является то, что лекарственное средство и связующее вещество образуют внутреннюю фазу, в то время как все другие эксципиенты добавляют в порошковой форме в качестве наружной фазы. Таким образом, предупреждается прилипаемость композиции и может быть достигнута достаточная прочность таблетки.
EA201692310A 2014-05-29 2015-05-27 Состав церитиниба EA036922B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462004359P 2014-05-29 2014-05-29
PCT/IB2015/053966 WO2015181739A1 (en) 2014-05-29 2015-05-27 Ceritinib formulation

Publications (2)

Publication Number Publication Date
EA201692310A1 true EA201692310A1 (ru) 2017-04-28
EA036922B1 EA036922B1 (ru) 2021-01-15

Family

ID=53298568

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692310A EA036922B1 (ru) 2014-05-29 2015-05-27 Состав церитиниба

Country Status (27)

Country Link
US (4) US20170112834A1 (ru)
EP (1) EP3148513B1 (ru)
JP (3) JP6679578B2 (ru)
KR (1) KR20170008239A (ru)
CN (1) CN106456640B (ru)
AR (1) AR100625A1 (ru)
AU (3) AU2015265470A1 (ru)
BR (1) BR112016027580A8 (ru)
CA (1) CA2948291A1 (ru)
CL (1) CL2016003047A1 (ru)
DK (1) DK3148513T3 (ru)
EA (1) EA036922B1 (ru)
EC (1) ECSP16096826A (ru)
ES (1) ES2792574T3 (ru)
HU (1) HUE048950T2 (ru)
IL (1) IL248835B (ru)
MX (1) MX2016015736A (ru)
PE (1) PE20170313A1 (ru)
PH (1) PH12016502272A1 (ru)
PL (1) PL3148513T3 (ru)
PT (1) PT3148513T (ru)
SG (1) SG11201609208UA (ru)
SI (1) SI3148513T1 (ru)
TN (1) TN2016000484A1 (ru)
TW (1) TWI721946B (ru)
UY (1) UY36140A (ru)
WO (1) WO2015181739A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106176752B (zh) * 2015-05-07 2020-06-23 石药集团中奇制药技术（石家庄）有限公司 色瑞替尼药物组合物
CN109381440A (zh) * 2018-11-15 2019-02-26 威海贯标信息科技有限公司 一种艾乐替尼组合物
CN113244236B (zh) * 2021-06-01 2023-02-03 上海市第一人民医院 色瑞替尼在制备治疗甲状腺相关眼病的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3632778A (en) * 1970-06-10 1972-01-04 Hoffmann La Roche Tablets containing l-dopa
MX2009006081A (es) * 2006-12-08 2009-06-17 Irmc Llc Compuestos y composiciones como inhibidores de cinasa de proteina.
ES2524009T3 (es) * 2006-12-08 2014-12-03 Irm Llc Compuestos y composiciones como inhibidores de la proteína quinasa
EP2090297A1 (en) * 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
CN106890147A (zh) * 2010-05-11 2017-06-27 田边三菱制药株式会社 含1‑(β‑D‑吡喃葡糖基)‑3‑(苯基噻吩基甲基)苯化合物的片剂

Also Published As

Publication number Publication date
HUE048950T2 (hu) 2020-09-28
IL248835A0 (en) 2017-01-31
IL248835B (en) 2020-05-31
TN2016000484A1 (en) 2018-04-04
AR100625A1 (es) 2016-10-19
DK3148513T3 (da) 2020-05-25
PH12016502272A1 (en) 2017-02-06
SG11201609208UA (en) 2016-12-29
BR112016027580A8 (pt) 2021-06-29
CL2016003047A1 (es) 2017-04-07
US20170112834A1 (en) 2017-04-27
PL3148513T3 (pl) 2020-08-24
JP2020114834A (ja) 2020-07-30
KR20170008239A (ko) 2017-01-23
ES2792574T3 (es) 2020-11-11
MX2016015736A (es) 2017-03-16
AU2018203007A1 (en) 2018-05-17
TW201613580A (en) 2016-04-16
UY36140A (es) 2016-01-08
CA2948291A1 (en) 2015-12-03
JP2022078236A (ja) 2022-05-24
AU2018203007B2 (en) 2019-07-18
JP7084955B2 (ja) 2022-06-15
PT3148513T (pt) 2020-05-27
JP2017520619A (ja) 2017-07-27
PE20170313A1 (es) 2017-04-18
AU2019232937A1 (en) 2019-10-10
WO2015181739A1 (en) 2015-12-03
JP6679578B2 (ja) 2020-04-15
EP3148513B1 (en) 2020-02-26
BR112016027580A2 (pt) 2017-08-15
EA036922B1 (ru) 2021-01-15
TWI721946B (zh) 2021-03-21
EP3148513A1 (en) 2017-04-05
AU2019232937B2 (en) 2020-10-15
US20200009141A1 (en) 2020-01-09
ECSP16096826A (es) 2018-04-30
US11000523B2 (en) 2021-05-11
AU2015265470A1 (en) 2016-11-24
US20210154194A1 (en) 2021-05-27
SI3148513T1 (sl) 2020-07-31
CN106456640B (zh) 2021-05-14
CN106456640A (zh) 2017-02-22
US20190022095A1 (en) 2019-01-24

Similar Documents

Publication Publication Date Title
PH12019500393A1 (en) Substituted pyrrolizine compounds and uses thereof
MX2020003825A (es) Formas de dosificacion solidas de palbociclib.
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
EA201890058A1 (ru) Производное глюкагона и композиция, содержащая длительно действующий конъюгат этого производного
TW201613911A (en) Heterocyclic compounds and uses thereof
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201690246A1 (ru) Ингибиторы аутотаксинов, содержащие ядро гетероароматическое кольцо-бензил-амидный цикл
EA201891336A1 (ru) Гетероарилгидроксипиримидиноны в качестве агонистов рецептора apj
BR112016021012A2 (pt) composições farmacêuticas de compostos terapeuticamente ativos.
EA201791293A1 (ru) Сайт-специфическое дозирование ингибитора btk
EA201600124A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
EA201790650A1 (ru) Лекарственная форма и способы применения абиратерона ацетата
EA201500821A1 (ru) Производные 2-замещенных-6-биарилметиламино-9-циклопентил-9н-пуринов, их использование в качестве лекарственных средств и фармацевтических составов
EA201692043A1 (ru) Лекарственная форма иммунодепрессанта
DK3821905T3 (da) Insulin indeholdende farmaceutiske sammensætninger
EA201691983A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов cb2
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
DK3229776T3 (da) Farmaceutisk sammensætning, der kombinerer mindst to særskilte nanopartikler og en farmaceutisk forbindelse, fremstilling og anvendelser deraf
IN2014CH00840A (ru)
EA201692310A1 (ru) Состав церитиниба
EA201692270A1 (ru) Производные нафтиридиндиона
EP3297636A4 (en) Pharmaceutical composition of carboplatin based co-crystals and use thereof
DK3655079T3 (da) Pulverinhalator til enkeltdosis
UA113977C2 (xx) Фармацевтична композиція з покращеною стабільністю

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM